BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2023 Earnings Conference Call February 26, 2024 8:30 AM ET Company Participants John Bluth - Chief Communications Officer Jon Stonehouse - Chief Executive Officer Ryan Arnold - Chief Medical Officer Charlie Gayer - Chief Commercial Officer Anthony Doyle - Chief Financial Officer Conference Call Participants Tazeen Ahmad - Bank of America Brian Abrahams - RBC Capital Markets Jessica Fye - JP Morgan Liisa Bayko - Evercore ISI Stacy Ku - TD Cowen Serge Belanger - ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 par value BCRX Nasdaq Global Select Market Emerging growth company o UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition pe ...

Company Performance - BioCryst Pharmaceuticals reported a quarterly loss of $0.28 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.24, but an improvement from a loss of $0.38 per share a year ago [1] - The company achieved revenues of $93.4 million for the quarter ended December 2023, exceeding the Zacks Consensus Estimate by 4.72% and up from $79.55 million year-over-year [1] - Over the last four quarters, BioCryst has surpassed consensus EPS estimates three times and has also topped consensus revenue estimates three times [1] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.25 on revenues of $85.97 million, and for the current fiscal year, it is -$0.67 on revenues of $406.94 million [4] - The estimate revisions trend for BioCryst is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [4] Industry Context - The Medical - Drugs industry, to which BioCryst belongs, is currently in the top 40% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [5] - Rigel Pharmaceuticals, another company in the same industry, is expected to report a quarterly loss of $0.04 per share, reflecting a significant year-over-year decline of 500%, with revenues projected at $33.5 million, down 34.7% from the previous year [5]

—ORLADEYO net revenue of $90.9 million for Q4 2023 and $326.0 million for FY 2023 (+30 percent y-o-y) — —2024 ORLADEYO net revenue expected to be between $380-$400 million— —Company expects operating profit in 2024, approaching positive EPS and positive cash flow in 2H 2025— RESEARCH TRIANGLE PARK, N.C., Feb. 26, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update. ...

RESEARCH TRIANGLE PARK, N.C., Feb. 23, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new analyses of real-world use of oral, once-daily ORLADEYO® (berotralstat) that showed patients who initiated ORLADEYO experienced rapid, substantial and sustained reductions in attack rates through 18 months of treatment regardless of the severity of their disease, their history of prior prophylaxis or their C1-inhibitor (C1-INH) level and function. The data are being presented in ...

RESEARCH TRIANGLE PARK, N.C., Feb. 21, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the TD Cowen 44th Annual Health Care Conference in Boston on Wednesday, March 6, 2024, at 10:30 a.m. ET and the Barclays 26th Annual Global Healthcare Conference in Miami on Tuesday, March 12, 2024, at 7:30 a.m. ET. Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst's website ...

RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Italian Medicines Agency, Agenzia Italiana del Farmaco (AIFA), has finalized reimbursement and recommended ORLADEYO® (berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older. With this recommendation, HAE patients in Italy now have access to the first oral, once-daily therapy for the routine prevent ...

RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2023 financial results on Monday, February 26, 2024. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webca ...

Core Insights - BioCryst Pharmaceuticals will present five abstracts on the real-world use of ORLADEYO® (berotralstat) for hereditary angioedema (HAE) at the 2024 AAAAI annual meeting [1] Group 1: Abstract Presentations - The first abstract discusses how berotralstat prophylaxis reduces HAE attack rates regardless of baseline attacks [1] - The second abstract highlights consistently low HAE attack rates with berotralstat, irrespective of prior prophylaxis [1] - The third abstract presents interim analysis from the Berolife Study, assessing the tolerability and effectiveness of berotralstat for long-term prophylaxis [1] - The fourth abstract evaluates adherence to berotralstat through a prospective survey conducted in community pharmacies [1] - The fifth abstract examines the real-world effectiveness of berotralstat in HAE patients with and without C1-inhibitor deficiency [1] Group 2: Product Information - ORLADEYO® (berotralstat) is the first and only oral therapy specifically designed to prevent HAE attacks in patients aged 12 years and older [2] - The drug functions as a plasma kallikrein inhibitor, with one capsule taken daily to prevent HAE attacks [2][3] Group 3: Safety Information - The safety and effectiveness of ORLADEYO for treating acute HAE attacks have not been established, and it should not be used for this purpose [4] - An increase in QT prolongation has been observed at dosages higher than the recommended 150 mg once daily [5] - Common adverse reactions in patients receiving ORLADEYO include abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease [5]

Core Insights - BioCryst Pharmaceuticals will present five abstracts on the real-world use of ORLADEYO® (berotralstat) for hereditary angioedema (HAE) at the 2024 AAAAI annual meeting [1] - ORLADEYO is the first oral therapy specifically designed to prevent HAE attacks in patients aged 12 and older [2][3] Group 1: Abstract Presentations - The first abstract discusses how berotralstat prophylaxis reduces HAE attack rates regardless of baseline attacks [1] - The second abstract highlights consistently low HAE attack rates with berotralstat, irrespective of prior prophylaxis [1] - The third abstract presents interim analysis from the Berolife Study on the tolerability and effectiveness of berotralstat for long-term prophylaxis [1] - The fourth abstract evaluates adherence to berotralstat through a prospective survey in community pharmacies [1] - The fifth abstract assesses the real-world effectiveness of berotralstat in HAE patients with and without C1-inhibitor deficiency [1] Group 2: Product Information - ORLADEYO is indicated for the prophylaxis of HAE attacks in adults and pediatric patients aged 12 years and older [3] - The drug works by decreasing the activity of plasma kallikrein, preventing HAE attacks with a once-daily capsule [2] - Safety information indicates that the effectiveness of ORLADEYO for acute HAE attacks has not been established, and it should not be used for such treatment [4] Group 3: Safety and Efficacy - Common adverse reactions in patients receiving ORLADEYO include abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease [5] - A reduced dosage of 110 mg is recommended for patients with moderate or severe hepatic impairment [5] - The drug is a moderate inhibitor of CYP2D6 and CYP3A4, necessitating monitoring for concomitant medications [6]